丘脑胶质瘤的显微外科解剖与手术入路。第2部分:最大安全切除改善丘脑胶质瘤预后——单中心经验
该单中心回顾性研究纳入2006至2020年42例丘脑胶质瘤患者,评估最大安全切除的可行性与预后。总体次全及全切率达95%,无手术死亡,2年总生存率低级别胶质瘤为90%、高级别胶质瘤为15%。多因素分析显示组织学分级、年龄和切除程度是与生存相关的独立预后因素。
要点
- 丘脑胶质瘤最大安全切除的次全及全切率为95%(40/42),无手术死亡。
- 术后暂时性运动障碍见于12例(28.6%),仅1例(2.4%)遗留轻度偏瘫。
- 2年总生存率低级别胶质瘤为90%,高级别胶质瘤为15%。
核心结论
- 丘脑胶质瘤处理具有挑战性,许多甚至多数神经外科医生避免切除,尤其是高级别胶质瘤。
- 本文结果证明切除可改善预后,尤其是年轻低级别胶质瘤患者。
- 作者因此主张对经过选择的丘脑胶质瘤患者采用最大安全切除,使用精心规划的手术入路、现代术中辅助手段和细致显微外科技术。
研究设计与样本
- 回顾性单中心研究,纳入2006年至2020年所有丘脑胶质瘤患者,共42例(男性26例,女性16例),其中儿童12例(29%)。
- 平均年龄36.0±21.4岁(中位30岁,范围3-73岁),肿瘤最大径中位45 mm(范围19-70 mm)。
- 采用单因素和多因素分析确定预后变量,并通过病例示例说明不同入路及复杂丘脑胶质瘤分期切除的理由。
主要发现
- 18例(43%)既往接受立体定向针吸肿瘤活检,显微外科切除后7例(39%)最终诊断发生改变。
- 最常见手术入路为经颞入路(29%)、前纵裂经胼胝体入路(29%)和顶上小叶入路(25%)。
- 总体次全及全切率为95%(n=40);低级别胶质瘤(I和II级)占三分之一,半数患者为胶质母细胞瘤。
- 无手术死亡;术后暂时性运动障碍见于12例(28.6%),除1例(2.4%)遗留轻度偏瘫外均在术后早期改善;2例因脑积水需脑脊液分流。
- 2年总生存率低级别胶质瘤患者为90%,高级别胶质瘤患者为15%;多因素分析显示组织学分级、年龄和切除程度是与生存相关的独立预后因素。
临床怎么用
- 作者主张对经过选择的丘脑胶质瘤患者采用最大安全切除,使用精心规划的手术入路、现代术中辅助手段和细致显微外科技术。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As presented in Part 1 of this series, thalamic gliomas (TGs) are deep-seated, difficult-to-access tumors surrounded by vital neurovascular structures. Given their high operative morbidity, TGs have historically been considered inoperable lesions. Although maximal safe resection (MSR) has become the treatment standard for lobar and even deep-seated mediobasal temporal and insular gliomas, the eloquent location of TGs has precluded this management strategy, with biopsy and adjuvant treatment being the mainstay. The authors hypothesized that MSR can be achieved with low morbidity and mortality for TGs, thus resulting in improved outcomes. METHODS: A retrospective single-center study was performed on all TG patients from 2006 to 2020. Clinical, imaging, and pathology reports were obtained. Univariate and multivariate analyses were performed to determine prognostic variables. Case examples illustrate various approaches and the rationale for staging resections of more complex TGs. RESULTS: A total of 42 patients (26 males, 16 females), among them 12 pediatric (29%) cases, were included. Their mean age was 36.0 ± 21.4 (median 30, range 3-73) years. The median maximal tumor diameter was 45 (range 19-70) mm. Eighteen patients (43%) had a prior stereotactic needle tumor biopsy, with the ultimate diagnosis changed for 7 patients (39%) following microsurgical resection. The most common surgical approaches were transtemporal (29%), anterior interhemispheric transcallosal (29%), and superior parietal lobule (25%). Overall, the combined subtotal and gross-total resection rate was 95% (n = 40). Low-grade gliomas (LGGs; grades I and II) comprised one-third of the group, whereas half of the patients had glioblastoma multiforme. There were no operative mortalities. Although temporary postoperative motor deficits were observed in 12 patients (28.6%), all improved during the early postoperative period except 1 (2.4%), who had mild residual hemiparesis. Two patients required CSF diversion for hydrocephalus. The 2-year overall survival rate was 90% for LGG patients and 15% for high-grade glioma (HGG) patients. Multivariate analysis revealed that histological grade, age, and extent of resection were independent prognostic factors associated with survival. CONCLUSIONS: Management of TGs is challenging, with resection avoided by many, if not most, neurosurgeons, especially for HGGs. The results reported here demonstrate improved outcomes with resection, particularly in younger LGG patients. The authors therefore advocate for MSR for a select cohort of TG patients using carefully planned surgical approaches, contemporary intraoperative adjuncts, and meticulous microsurgical techniques.
引用
- Martínez Santos JL, Aljuboori Z, Richardson AM, et al. Microsurgical anatomy and approaches to thalamic gliomas. Part 2: Maximal safe resection of thalamic gliomas improves outcomes. A single-center experience. J Neurosurg. 2024. PMID: 39029116. doi:10.3171/2024.3.JNS232067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。